The University of Chicago Header Logo

Connection

James Dignam to Randomized Controlled Trials as Topic

Back to Details
This is a "connection" page, showing publications James Dignam has written about Randomized Controlled Trials as Topic.
James Dignam
Connection Strength
2.234
Randomized Controlled Trials as Topic
  1. Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
    View in: PubMed
    Score: 0.639
  2. Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group. J Natl Cancer Inst. 2010 Feb 24; 102(4):279-80; author reply 280-2.
    View in: PubMed
    Score: 0.235
  3. Early viewing of noninferiority trials in progress. J Clin Oncol. 2005 Aug 20; 23(24):5461-3.
    View in: PubMed
    Score: 0.172
  4. On the use of external controls in clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 01; 2025(68):30-34.
    View in: PubMed
    Score: 0.168
  5. Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 Dec; 201:110532.
    View in: PubMed
    Score: 0.163
  6. Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024 05 03; 26(5):796-810.
    View in: PubMed
    Score: 0.158
  7. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials. 1998 Dec; 19(6):575-88.
    View in: PubMed
    Score: 0.109
  8. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012 Apr 15; 18(8):2301-8.
    View in: PubMed
    Score: 0.068
  9. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):595-602.
    View in: PubMed
    Score: 0.054
  10. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006 Nov 15; 98(22):1647-54.
    View in: PubMed
    Score: 0.047
  11. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006 Jun; 97(3):245-54.
    View in: PubMed
    Score: 0.044
  12. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025 Sep; 88(3):277-290.
    View in: PubMed
    Score: 0.043
  13. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2025 Feb; 87(2):217-224.
    View in: PubMed
    Score: 0.040
  14. Semiparametric models for cumulative incidence functions. Biometrics. 2004 Mar; 60(1):182-90.
    View in: PubMed
    Score: 0.039
  15. Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. J Clin Oncol. 2003 Feb 01; 21(3):413-20.
    View in: PubMed
    Score: 0.036
  16. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001; (30):36-43.
    View in: PubMed
    Score: 0.031
  17. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
    View in: PubMed
    Score: 0.030
  18. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999 Nov 17; 91(22):1933-40.
    View in: PubMed
    Score: 0.029
  19. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104.
    View in: PubMed
    Score: 0.025
  20. Assessing treatment benefit with competing risks not affected by the randomized treatment. Stat Med. 2015 Jan 30; 34(2):265-80.
    View in: PubMed
    Score: 0.021
  21. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012 Jul; 14(7):910-8.
    View in: PubMed
    Score: 0.017
  22. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506.
    View in: PubMed
    Score: 0.017
  23. Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol. 2010 May 20; 28(15):2544-8.
    View in: PubMed
    Score: 0.015
  24. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72.
    View in: PubMed
    Score: 0.010
  25. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001 Aug; 28(4):400-18.
    View in: PubMed
    Score: 0.008
  26. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001 Jan 17; 93(2):112-20.
    View in: PubMed
    Score: 0.008
  27. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001; (30):62-6.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.